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a b s t r a c t
A patient with germline von Hippel-Lindau (VHL) gene alteration and history of multiple tumors present
with classical paraneoplastic syndrome (PNS) associated with renal cell carcinoma (RCC). She underwent
open nephron sparing surgery with resolution of symptoms. She remained without recurrence of RCC for
the initial 2 years of her follow-up. To the best of our knowledge, this case represents the first in which
PNS was specifically resolved using a partial nephrectomy in a patient with VHL. This case report
provides initial evidence for the potential role of nephron sparing surgery in the management of para-
neoplastic symptoms associated with hereditary RCC.
 2017 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Renal cell carcinoma (RCC), accounts for 85% of renal neoplasms
with an incidence of more than 60,000 new cases yearly.1 As many
as one-third of patients with RCC have reported symptoms of
paraneoplastic syndrome (PNS).1 The presence of paraneoplastic
syndromes with RCC does not indicate occult metastases, nor is it a
contraindication for surgery; however, it may correlate with a
worse prognosis.1
von Hippel-Lindau (VHL) is a hereditary condition associated
withmultiple, recurrent clear-cell RCC.2We report the case of a VHL
patient with a rapidly growing RCC and clinical evidence of severe
PNS which resolved following partial nephrectomy.
Case presentation
A 49-year-old female with a history of von Hippel-Lindau with a
germline VHL gene mutation, presented to the National Institutes of
Health (NIH) with persistent nausea, vomiting, fevers and symp-
tomatic, transfusion-dependent anemia. Previously, she had been
followed for her VHL at NIH for more than 12 years. At the time of
admission, the patient had experienced 5months of episodic fevers,
chills with increasing frequency and duration. The patient also
reported progressive fatigue, anorexia and a 15e20 lbs uninten-
tional weight-loss. Upon admission, the patient was febrile (37.8 C)
with profound anemia and orthostatic hypotension.
The patient’s past medical history included the diagnosis of VHL
when retinal angiomas were identified at the age of 9. Additional
medical history was notable for breast and lung cancers in addition
to VHL-associated tumors (bilateral RCC, central nervous system
hemangioblastomas, and pancreatic neuroendocrine tumors).
Surgical history included left breast lumpectomy and radiation, left
lingulectomy and mediastinal node dissection, multiple bilateral
partial nephrectomy (the last intervention was 8 years prior in the
ipsilateral kidney), and multiple neurosurgical interventions. The
Abbreviations and acronyms: PNS, Paraneoplastic syndrome; RCC, Renal cell
carcinoma; VHL, von Hippel-Lindau disease.
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patient reported no prior history of paraneoplastic syndromes with
previous malignancies.
A comprehensive infectious, gastrointestinal, and pulmonary
workup failed to reveal a clear etiology of her symptoms. A
computed tomography (CT) scan of the chest/abdomen/pelvis
revealed a right upper pole RCC that grown dramatically compared
to a previous CT performed 5 months earlier. Other enhancing le-
sions in both kidneys remained unchanged (Fig. 1). Nuclear scin-
tigraphy also noted the right renal mass as well as stable
nonspecific retroperitoneal adenopathy but no evidence of soft
tissue or bone metastases. Renal mass biopsy showed poorly
differentiated, Fuhrman grade 4 RCC with focal clear cell features
and extensive necrosis (Fig. 2). Immunohistochemistry staining was
positive for CD10 in tumor cells, and negative for CK7, TTF-1, ER, and
PR. In the absence of any infectious, hematologic or pulmonary
etiology, we suspected this neoplasm to be the cause of her recur-
ring fevers and PNS as a diagnosis of exclusion. This conclusionwas
corroborated by consultants from infectious disease, pulmonology,
thoracic oncology and internal medicine. The summary of the
patient’s additional hospital evaluation is presented in Table 1.
The patient underwent an open right partial nephrectomy to
excise the renal mass. During the procedure, the right upper pole
5.5 cm mass was excised using wide margins due to the tumor’s
aggressive growth kinetics. Four other solid tumors were identified
using intraoperative ultrasound and enucleated per our previously
described technique.2
The postoperative hospitalization was uneventful, and the
patient was discharged approximately 2 weeks after surgery once
her fevers, nausea and vomiting had resolved. At the patient’s
3 month follow up visit, internal medicine consultation confirmed
resolution of paraneoplastic syndrome symptoms (anorexia,
transfusion dependent anemia).
Her follow up HCT had normalized to 42.0%. While the patient
remained PNS symptom free over 2 years follow-up, she has
recently been diagnosedwith a locally recurrent right kidney tumor
with hepatic metastasis.
Discussion
Paraneoplastic syndromes are rare, particularly in hereditary
RCC conditions, however being familiar with their symptomatology
is important to minimize patient morbidity and for surgical plan-
ning,3 and rapid recognition of PNS symptoms can lead to the
diagnosis of a biologically aggressive neoplasm.3 The patient in this
case presented with fever, one of the most common constitutional
manifestations of paraneoplastic syndrome, present in 20e30% of
RCC cases.3 It is thought that fever and other constitutional symp-
toms of paraneoplastic syndrome are caused by cytokines and
pyrogens, such as tumor necrosis factor-b, interleukin-6 (IL-6), and
IL-1, released by the tumor cells.3 Historically, paraneoplastic syn-
dromes arising from RCC have been treated definitively with
nephrectomy which has been shown to often reverse signs and
symptoms of the PNS.3 However, since VHL typically manifests in
bilateral and multifocal RCC and renal cysts, identifying the caus-
ative tumor may be challenging.4 Fortunately, an extensive review
of the literature revealed no reported cases of paraneoplastic syn-
dromes in VHL patients suggesting this a rare event. To the best of
our knowledge, this case represents the first in which paraneo-
plastic syndrome was specifically resolved using a partial
nephrectomy in a patient with VHL.
Before surgical intervention, the patient’s condition had dete-
riorated dramatically, believed to be the result of her rapidly
growing renal mass, which was identified because of the radio-
graphic surveillance that is commonplace for VHL patients.4 The
rapid growth was concerning and unusual for VHL-associated tu-
mors which typically grow only 3e5 mm per year in longest
dimension.4 After the partial nephrectomy, the patient’s paraneo-
plastic syndrome resolved and her condition dramatically
improved. Use of intraoperative ultrasound to identify and
enucleate numerous solid tumors during the partial nephrectomy,
simultaneously delayed the need for further surgical intervention
Figure 1. Preoperative axial computed tomography scans revealed a renal mass located in the right posterior upper pole that grew from approximately 2 cm (A) to 5 cm (B)
in 5 months.
Figure 2. Renal cell carcinoma, clear cell type, Fuhrman nuclear grade 2.
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while also ensuring the removal of the tumor cells secreting the
causative cytokines, effectively managing the patient’s paraneo-
plastic syndrome. While the patient’s subsequent development of
metastases is most likely due to the aggressive biology of this tumor
rather than the choice of partial nephrectomy rather than radical
nephrectomy,5 further studies are needed to confirm that.
Conclusion
To the best of our knowledge, this case represents the first in
which paraneoplastic syndrome was specifically resolved using a
partial nephrectomy in a patient with VHL. We believe this case
represents the potential of nephron sparing surgery for managing
the paraneoplastic symptoms associated with hereditary RCC.
Consent
This patient is followed by the Clinical Manifestations and
Molecular Bases of Heritable Urologic Malignant Disorders (Trial
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Table 1
Summary of hospital evaluation and results.
Metabolic Metabolic: Naþ 138, Kþ 4.2, Cl- 99, CO2 24, aglucose 112
(74e106 mg/dL), BUN 15, creatinine 0.86, eGFR 79, aCaþ
2.41, Mgþ 0.86, phosphorus 2.7
Hepatic: aAlbumin 2.8 (3.5e5.2 g/dL), aalk phos 601 (35
e105 U/L), ALT 17, AST 13, T.Bili 1.1, aD.Bili 0.8 (0e0.3 mg/
dL); Coag: aPT 16.2 (11.6e15.2 sec), aaPTT 48.7 (25.3
e37.3 sec),
Lipid: cholesterol 135, HDL 10, LDL 98, triglycerides 135.
Infectious C-peptide 4.1
UA: protein 2þ (100 mg/dL), leukocyte esterase 3þ, WBC
141, squamous epithelial cells 51
Hematologic CBC: aHgb 9.5 g/dL (reduced 11.4 g/dL one month prior),
aHct 31.3%, WBC of 9.31  103, platelet 653 K/uL,
Anemia: MCV 81.5, reticulocyte count 1.19 (0.5e1.70%),
absolute reticulocyte 45.5 (16.4e77.6 K/uL), aerythropoietin
26.7 (2.6e18.5 mIU/ML), ahaptoglobin 694 (30e200 mg/dL)
LDH 138 U/L, airon 24 (37e145 mcg/dL), atransferrin 93
(200e360 mg/dL), asaturation 18% (20e50%), aferritin 4964
(13e150 mcg/L), serum vitamin B12 439 (200e900 pg/mL).
Peripheral blood smear: aconfirmed thrombocytosis, a few
red blood cells with central pallor, and many normal
appearing red blood cells, consistent with prior transfusion.
Bone marrow biopsy: performed 3months prior was within
normal range.
Gastrointestinal Colonoscopy and upper endoscopy did not identify any
source of bleeding.
Pulmonary No pulmonary pathology was noted on CT chest. Thoracic
oncology consult did not identify any potential thoracic
etiology.
Endocrine HgbA1c 5.7% with estimated average glucose 117 mg/dL,
serum insulin level 9.4, TSH 1.0, intact PHT 20.9, FSH 24.5,
LH 20.5, serum estradiol 38.8, serum progesterone 0.5
a Significant and/or abnormal findings. (Nonmetastatic hepatic dysfunction,
hypoglycemia, microcytic hypochromic iron deficiency anemia w/elevated epo).
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